EGFR mutations as a predictive marker of cytotoxic chemotherapy
Lung Cancer, 04/26/2012Park JH et al.
The current data indicate that lung cancer patients with Epidermal growth factor receptor (EGFR)–mutations had longer progression–free survival with taxane than gemcitabine when receiving a platinum–based doublet regimen. The predictive meaning of EGFR mutations for cytotoxic chemotherapy should be further investigated.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.